17-4934224-G-A
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_StrongPP5_Very_Strong
The NM_000173.7(GP1BA):c.1620G>A(p.Trp540*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000137 in 1,461,346 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000173.7 stop_gained
Scores
Clinical Significance
Conservation
Publications
- congenital myasthenic syndromeInheritance: AR Classification: DEFINITIVE Submitted by: Illumina
- congenital myasthenic syndrome 4AInheritance: AD, AR Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), PanelApp Australia
- congenital myasthenic syndrome 4BInheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), PanelApp Australia
- congenital myasthenic syndrome 4CInheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp
- postsynaptic congenital myasthenic syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000173.7. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GP1BA | NM_000173.7 | MANE Select | c.1620G>A | p.Trp540* | stop_gained | Exon 2 of 2 | NP_000164.5 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GP1BA | ENST00000329125.6 | TSL:1 MANE Select | c.1620G>A | p.Trp540* | stop_gained | Exon 2 of 2 | ENSP00000329380.5 | ||
| CHRNE | ENST00000649830.1 | c.-888+118C>T | intron | N/A | ENSP00000496907.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.0000281 AC: 7AN: 248922 AF XY: 0.0000296 show subpopulations
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461346Hom.: 0 Cov.: 37 AF XY: 0.0000151 AC XY: 11AN XY: 726916 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Bernard-Soulier syndrome, type A1 Pathogenic:1
not provided Pathogenic:1
This sequence change creates a premature translational stop signal (p.Trp540*) in the GP1BA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 113 amino acid(s) of the GP1BA protein. This variant is present in population databases (rs267606849, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with Bernard-Soulier syndrome (PMID: 9233564, 9639514). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is also known as c.2078G>A (p.W498*). ClinVar contains an entry for this variant (Variation ID: 4157). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects GP1BA function (PMID: 9639514). For these reasons, this variant has been classified as Pathogenic.
Bernard Soulier syndrome Pathogenic:1
The c.1620G>A (p.Trp540Ter) variant in GP1BA is a nonsense variant that may cause a premature stop codon that is predicted to escape nonsense mediated decay. However the truncation includes the functionally important transmembrane domain (removes amino acids 540-553) in a gene where loss-of-function is an established disease mechanism (PVS1_Strong; PMID:9639514). The Grpmax Filtering allele frequency in gnomAD v4.1.0 is 0.000009540 (based on 18/1179684 alleles) in the European (non-Finnish) population, which is lower than the ClinGen PD VCEP threshold (<0.0001114; PM2_Supporting). Surface expression of GP1a measured by flow cytometry in CHO cells transiently co-transfected with the p.Trp540Ter variant in GP1a and wild type GP1b, and GP9 was barely detectable compared to controls, indicating that this variant impacts protein function (PMID:9639514)(PS3_supporting). This variant has been detected in at least 6 individuals with Bernard-Soulier syndrome. At least one individual had excessive mucocutaneous bleeding and macrothrombocytopenia and absent expression of GPIba measured by flow cytometry (PP4 - PMID:25370924). Two of those individuals were homozygous for this variant (PMID:25370924, 9233564). Two individuals were compound homozygous for this variant and the p.Cys81Arg variant and confirmed in trans by family testing, but was used for that curation (PMID:25370924). Another proband (different publication and authorship) was compound homozygous for this variant and the p.Cys81Arg variant and confirmed in trans by family testing, but was used for this curation (PMID: 9639514) for a total of 2 points (PM3). The variant has been reported to segregate in a homozygous proband plus 2 compound heterozygotes (PMID:25370924) and a proband plus 1 additional compound heterozygous affected sibling (PMID: 9639514) meeting PP1_strong. In summary, this variant meets the criteria to be classified as pathogenic for Bernard-Soulier syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PVS1_strong, PM3, PP4, PP1_moderate, PM2_supporting, PS3_supporting (Platelet VCEP GP1BA specifications version 1).
Bernard Soulier syndrome;C1280798:Pseudo von Willebrand disease;C1847711:Nonarteritic anterior ischemic optic neuropathy, susceptibility to;C3277076:Bernard-Soulier syndrome, type A2, autosomal dominant Pathogenic:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at